NCT07024862 2025-06-17
Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
Bristol-Myers Squibb
Active not recruiting
Bristol-Myers Squibb
Asan Medical Center